J Am Coll Radiol. 2016 Apr;13(4):389-400. doi: 10.1016/j.jacr.2015.12.019. Epub 2016 Feb 24.
Roberts CC1, Kransdorf MJ2, Beaman FD3, Adler RS4, Amini B5, Appel M6, Bernard SA7, Fries IB8, Germano IM9, Greenspan BS10, Holly LT11, Kubicky CD12, Shek-Man Lo S13, Mosher TJ7, Sloan AE14, Tuite MJ15, Walker EA7, Ward RJ16, Wessell DE17, Weissman BN18.
Appropriate imaging modalities for the follow-up of malignant or aggressive musculoskeletal tumors include radiography, MRI, CT, (18)F-2-fluoro-2-deoxy-D-glucose PET/CT, (99m)Tc bone scan, and ultrasound. Clinical scenarios reviewed include evaluation for metastatic disease to the lung in low- and high-risk patients, for osseous metastatic disease in asymptomatic and symptomatic patients, for local recurrence of osseous tumors with and without significant hardware present, and for local recurrence of soft tissue tumors. The timing for follow-up of pulmonary metastasis surveillance is also reviewed. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Copyright © 2016 American College of Radiology. Published by Elsevier Inc. All rights reserved.